Last reviewed · How we verify
NCT04569630: HEADWIND
The HEADWIND Study - Part 2
NA trial testing Controlled hypoglycaemic state while driving in Diabetes in 22 participants. Completed in 28 May 2021.
27 May 2021
Quick facts
| Lead sponsor | Insel Gruppe AG, University Hospital Bern |
|---|---|
| Phase | NA |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | other |
| Enrollment | 22 |
| Start date | 1 October 2020 |
| Primary completion | 27 May 2021 |
| Estimated completion | 28 May 2021 |
| Sites | 1 location across Switzerland |
Drugs / interventions tested
- Controlled hypoglycaemic state while driving
Conditions studied
- Diabetes — all drugs for Diabetes →
- Diabetes Mellitus, Type 1 — all drugs for Diabetes Mellitus, Type 1 →
Sponsor
Insel Gruppe AG, University Hospital Bern
Who can join
Adults 21 to 60, any sex, with Diabetes or Diabetes Mellitus, Type 1. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
To analyse driving behavior of individuals with type 1 diabetes in eu- and progressive hypoglycaemia while driving in a real car. Based on the driving variables provided by the car the investigators aim at establishing algorithms capable of discriminating eu- and hypoglycemic driving patterns using machine learning neural networks (deep machine learning classifiers).
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
Effectiveness and User Perception of an In-Vehicle Voice Warning for Hypoglycemia: Development and Feasibility Trial.
Bérubé C, Lehmann VF, Maritsch M, Kraus M, et al · · 2024 · cited 3× · PMID 38194257 · DOI 10.2196/42823
Verify or expand the search:
- PubMed search for NCT04569630
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Controlled hypoglycaemic state while driving
Trials testing the same drug.
- NCT05308095 — The HEADWIND Study - Part 4 · NA · completed
Other recruiting trials for Diabetes
Currently open trials in the same condition.
- NCT07272837 — Impact of Semaglutide (Ozempic/Wegovy®) on Heart and Muscle Mass · recruiting
- NCT07479134 — Production of Stem Cells for the Generation of Pancreatic Cells · NA · recruiting
- NCT07441655 — Families Implementing Good Health Traditions for Life · NA · recruiting
- NCT06724172 — CHIME: Comparing Health Interventions for Maternal Equity · NA · recruiting
- NCT07417865 — ECHO Diabetes FQHC · recruiting
Other Insel Gruppe AG, University Hospital Bern trials
Trials by the same sponsor.
- NCT06546384 — GLP-1 RA on Alcohol Consumption, Metabolism and Liver Parameters in Patients With Obesity and Fatty Liver Disease · NA · not yet recruiting
- NCT07524049 — Giving Children a Voice in Paediatric Anaesthesia · not yet recruiting
- NCT07415668 — Motor Eloquent Navigated Transcranial Magnetic Stimulation for Radiosurgery Planning · NA · not yet recruiting
- NCT07478536 — Stockholm3 Test Validation in Men on Active Surveillance in Switzerland (CHAS3 Trial) · not yet recruiting
- NCT07201506 — Real-Time Intracardiac Echocardiography for Ventricular Arrhythmia Ablation · NA · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT04569630 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Insel Gruppe AG, University Hospital Bern
- Last refreshed: 29 June 2021
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04569630.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing